CliffBio
biologic

Ixinity

Coagulation Factor IX (Recombinant)

Loss of exclusivityApril 2027projected — 12-year biologic exclusivity estimate
CompanyMedexus Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameIxinity
Active ingredientCoagulation Factor IX (Recombinant)
Strength1000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2015
Marketing statusRx

More from Medexus Pharma

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.